PUBLICATION
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance
- Authors
- Colombo, M., Garavelli, S., Mazzola, M., Platonova, N., Giannandrea, D., Colella, R., Apicella, L., Lancellotti, M., Lesma, E., Ancona, S., Palano, M.T., Barbieri, M., Taiana, E., Lazzari, E., Basile, A., Turrini, M., Pistocchi, A., Neri, A., Chiaramonte, R.
- ID
- ZDB-PUB-191005-3
- Date
- 2019
- Source
- Haematologica 105(7): 1925-1936 (Journal)
- Registered Authors
- Keywords
- Bone Marrow Microenvironment, Multiple Myeloma, Notch, drug resistance, tumor microenvironment
- MeSH Terms
-
- Animals
- Bone Marrow
- Cell Line, Tumor
- Drug Resistance
- Humans
- Jagged-1 Protein/genetics*
- Jagged-2 Protein/genetics*
- Multiple Myeloma*/drug therapy
- Multiple Myeloma*/genetics
- Receptors, Notch
- Tumor Microenvironment
- Zebrafish
- Zebrafish Proteins/genetics
- PubMed
- 31582544 Full text @ Haematologica
Citation
Colombo, M., Garavelli, S., Mazzola, M., Platonova, N., Giannandrea, D., Colella, R., Apicella, L., Lancellotti, M., Lesma, E., Ancona, S., Palano, M.T., Barbieri, M., Taiana, E., Lazzari, E., Basile, A., Turrini, M., Pistocchi, A., Neri, A., Chiaramonte, R. (2019) Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica. 105(7):1925-1936.
Abstract
Multiple myeloma is still incurable due to an intrinsic aggressiveness or, more frequently, to the interactions of malignant plasma cells with bone marrow microenvironment. Myeloma cells educate bone marrow cells to support neoplastic cell growth, survival, acquisition of drug resistance resulting in disease relapse. Myeloma microenvironment is characterized by Notch signaling hyperactivation due to the increased expression of Notch1 and 2 and the ligands Jagged1 and 2 in tumor cells. Notch activation influences myeloma cell biology and promotes the reprogramming of bone marrow stromal cells. In this work we demonstrate, by in vitro, ex vivo and using a zebrafish multiple myeloma model, that Jagged inhibition causes a decrease in both myeloma-intrinsic and stromal cell-induced resistance to currently used drugs, i.e. bortezomib, lenalidomide and melphalan. The molecular mechanism of drug resistance involves the chemokine system CXCR4/SDF1α. Myeloma cell-derived Jagged ligands trigger Notch activity in bone marrow stromal cells. These, in turn, secrete higher levels of SDF1α in the bone marrow microenvironment increasing CXCR4 activation in myeloma cells, which is further potentiated by the concomitant increased expression of this receptor induced by Notch activation. Consistently with the augmented pharmacological resistance, SDF1α boosts the expression of BCL2, Survivin and ABCC1. These results indicate that a Jagged-tailored approach may contribute to disrupting the pharmacological resistance due to intrinsic myeloma cell features or to the pathological interplay with bone marrow stromal cells and, conceivably, improve patients' response to standard-of-care therapies.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping